Literature DB >> 22341844

Complications of PORT-A-CATH® in patients with sickle cell disease.

Salam Alkindi1, Samaa Matwani, Alghalia Al-Maawali, Buthaina Al-Maskari, Anil Pathare.   

Abstract

BACKGROUND: Red cell exchange/transfusion is frequently used in the management of patients with medical complications related to acute severe sickle cell disease (SCD). However, peripheral venous access is often difficult without central venous catheters (CVCs) in adult patients with moderate or severe SCD. AIMS: To review our experience with the use of the PORT-A-CATH(®) device in sixteen patients with SCD undergoing exchange or simple transfusions.
METHODS: Among a cohort of 550 patients who frequently visited the inpatient service, sixteen SCD patients required the insertion of a PORT-A-CATH(®) device. These patients included 3 males and 13 females, aged 25-44 years [31.1 ± 2.3; mean ± SD]. A total of 24 PORT-A-CATH(®) devices were implanted in these 16 patients during the study period. Eleven patients had 1 device implanted, three patients had 2 devices, one patient had 3 devices, and one patient had 4 devices implanted.
RESULTS: Out of the 24 devices implanted, 17 required removal, due to either infection associated with sepsis and/or thrombosis. The organisms involved were Candida spp. (3), C. Parapsilosis (2), C. albicans (1), C. famata (1), C. lusitanice (1), Staphylococcus spp. (6), and S. aureus (3), as well as the coagulase-negative Staphylococcus (2), alpha hemolytic Streptococcus (1), Diphtheroid bacilli (2), Pseudomonas aeruginosa (2), Ps. Spp. (3), Escherichia coli (3), Klebsiella oxytoca (1), Klebsiella pneumoniae (1), Klebsiella spp. (1), Serratia liquefaciens (1), Serratia fanticola (1), Achromobacter spp. (2) Chromobacterium violaceum (1), Delftia acidovirans (1), Stenotrophomonas maltophile (1), Alcaligenes faecalis (1), and Enterobacter cloacae (1). Two episodes of documented thrombosis were observed. One case presented with right atrial thrombosis/SVC syndrome and the other case presented with left upper arm thrombosis. Two patients died with ports in situ, while five patients had ports in place at the time of this study. The median working life of the ports was 688.5 days (range: 39-3925). The rate of infective complications was 2.63 infections per 1000 catheter days, and the number of infections was significantly correlated with the number of ports [Pearson's r=0.66; p<0.01]. DISCUSSION: Our results suggest that patients with SCD suffer infective complications associated with the PORT-A-CATH(®), which often necessitate its removal. Although these devices are extremely useful, their optimal beneficial potential is only realized if the patients receive proper care at special centers well-versed in the maintenance of such devices by experienced staff. Copyright Â
© 2011 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22341844     DOI: 10.1016/j.jiph.2011.10.004

Source DB:  PubMed          Journal:  J Infect Public Health        ISSN: 1876-0341            Impact factor:   3.718


  9 in total

Review 1.  Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know.

Authors:  Rakhi P Naik; Michael B Streiff; Sophie Lanzkron
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

2.  Bloodstream Infections in Children With Sickle Cell Disease: 2010-2019.

Authors:  Marianne E Yee; Kristina W Lai; Nitya Bakshi; Joanna K Grossman; Preeti Jaggi; Alexander Mallis; Yun F Wang; Robert C Jerris; Peter A Lane; Inci Yildirim
Journal:  Pediatrics       Date:  2022-01-01       Impact factor: 7.124

3.  Respiratory Viral Infections in Sickle Cell Anemia: Special Emphasis on H1N1 Co-infection.

Authors:  Salam Alkindi; Taqwa Al-Yahyai; Sameer Raniga; Mohamed Rachid Boulassel; Anil Pathare
Journal:  Oman Med J       Date:  2020-11-07

4.  Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication.

Authors:  Rakhi P Naik; Michael B Streiff; Carlton Haywood; Julie A Nelson; Sophie Lanzkron
Journal:  Am J Med       Date:  2013-05       Impact factor: 4.965

5.  Thromboprophylaxis Reduced Venous Thromboembolism in Sickle Cell Patients with Central Venous Access Devices: A Retrospective Cohort Study.

Authors:  Stéphanie Forté; Gonzalo De Luna; Jameel Abdulrehman; Nafanta Fadiga; Olivia Pestrin; Anne-Laure Pham Hung d'Alexandry d'Orengiani; John Chinawaeze Aneke; Henri Guillet; Dalton Budhram; Anoosha Habibi; Richard Ward; Pablo Bartolucci; Kevin H M Kuo
Journal:  J Clin Med       Date:  2022-02-23       Impact factor: 4.241

6.  Portacath Implantation in Ghana: Initial Experience at the Komfo Anokye Teaching Hospital in Kumasi.

Authors:  Isaac Okyere; Perditer Okyere; Sanjeev Singh; Samuel Gyasi Brenu
Journal:  Clin Med Insights Case Rep       Date:  2022-03-22

7.  Predicting risk factors for thromboembolic complications in patients with sickle cell anaemia - lessons learned for prophylaxis.

Authors:  Salam Alkindi; Anwaar R Al-Ghadani; Samah R Al-Zeheimi; Said Y Alkindi; Naglaa Fawaz; Samir K Ballas; Anil V Pathare
Journal:  J Int Med Res       Date:  2021-12       Impact factor: 1.671

8.  Ambulatory management of pre- and extensively drug resistant tuberculosis patients with imipenem delivered through port-a-cath: A mixed methods study on treatment outcomes and challenges.

Authors:  Vijay Vinayak Chavan; Alpa Dalal; Sharath Nagaraja; Pruthu Thekkur; Homa Mansoor; Augusto Meneguim; Roma Paryani; Pramila Singh; Stobdan Kalon; Mrinalini Das; Gabriella Ferlazzo; Petros Isaakidis
Journal:  PLoS One       Date:  2020-06-16       Impact factor: 3.240

Review 9.  Life-Threatening Infectious Complications in Sickle Cell Disease: A Concise Narrative Review.

Authors:  Dominik Ochocinski; Mansi Dalal; L Vandy Black; Silvana Carr; Judy Lew; Kevin Sullivan; Niranjan Kissoon
Journal:  Front Pediatr       Date:  2020-02-20       Impact factor: 3.418

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.